SESSION R.A. II (President and CEO) reported 1 transaction at TAYSHA GENE THERAPIES, INC.
Review the transaction codes below to understand the nature of each event.
Filed: 3/8/2023ACC: 0001209191-23-017342
DirectorOfficer10% Owner· President and CEO
Since Sep 2020
+51.80K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
251.30K acquired · 199.50K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
+251.30K
Price / share
—
Trade value
—
% of position
2.7%
3/6/2023
9.17M→9.42M
Total
Net shares
+251.30K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/6/2023 | J · J | +251.30K | — | — | 2.7% | 9.17M | 9.42M |
| Total | +251.30K | $0.00 | ||||||
Derivative Transactions1
Employee Stock Option (right to buy)
Direct
Converts to
Common Stock
199.50K shares
Shares
−199.50K
Strike price
1.95
Held after
0.00
Exercisable
—
3/6/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) Direct | Common Stock199.50K shares | 3/6/2023 | D · Disposition | −199.50K | 1.95 | — | 0.00 |
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned141.09K
Common Stock
IndirectShares owned141.09K
Total
282.18K indirect282.18K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 141.09K | Indirect |
| Common Stock | 141.09K | Indirect |
| Total | 282.18K | 282.18K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported